search
Back to results

Therapy of Obesity and Diabetes Mellitus Type 2 (TADIA)

Primary Purpose

Obesity, Diabetes Type 2, Weight Loss

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Structured weight-loss program
Sponsored by
University Medicine Greifswald
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Formula diet

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • known type 2 diabetes
  • body-mass-index between 27 and 45 kg/m²

Exclusion Criteria:

  • treatment with incretin mimetic drugs < 3 month
  • pregnancy
  • immobilization
  • severe heart, liver or renal failure
  • dementia
  • eating disorder
  • alcoholism

Sites / Locations

  • University Medicine Greifswald

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention

Arm Description

Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks

Outcomes

Primary Outcome Measures

Change in HbA1c value

Secondary Outcome Measures

Change in weight
Change in body-mass-index
Change in waist circumference
Change in hip circumference
Change in body composition
Body composition will be assessed with bioimpedance
Change in fat fractions of abdominal organs
Fat fraction of abdominal organs will be assessed with magnet resonance imaging
Change in visceral fat volume
Visceral fat volume will be assessed with magnet resonance imaging
Change in fasting glucose
Change in fasting insulin
Change in triglycerides
Change in cholesterol
Change in HDL cholesterol
Change in LDL cholesterol
Change in alanine transaminase
Change in aspartate transaminase
Change in gamma-glutamyl transferase
Change in alkaline phosphatase
Change in uric acid
Change in 25-hydroxy-vitamine d3
Change in 1,25-dihydroxy-vitamine d3
Change in plasma calcium
Change in plasma phosphate
Change in insulin-like growth factor-1
Change in testosterone
Change in sex hormone-binding globulin
Change in quality of life
Quality of life was determined using SF-12
Change in sleep quality
Sleep quality was determined using the Pittsburgh sleep quality index
Change in diet history
7-day food record brought in at weeks 0 and 15 will be analyzed for macronutrient intake

Full Information

First Posted
November 1, 2016
Last Updated
November 18, 2016
Sponsor
University Medicine Greifswald
search

1. Study Identification

Unique Protocol Identification Number
NCT02970838
Brief Title
Therapy of Obesity and Diabetes Mellitus Type 2
Acronym
TADIA
Official Title
Evaluation of a Structured Weight-loss Program for Therapy of Obesity and Diabetes Mellitus Type 2
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
November 2012 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
May 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Medicine Greifswald

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate a standardized weight-loss program as treatment option for obesity and type 2 diabetes, changes in body composition and metabolic control are investigated in obese patients with diabetes.
Detailed Description
Men and women with obesity and diabetes mellitus type 2 are invited to join a standardized weight-loss program (six weeks of formula diet, followed by the reintroduction of regular food with gradually increasing energy intake over nine weeks) for a duration of 15 weeks. All subjects undergo bioelectrical impedance analyses to investigate body composition and magnet resonance imaging to measure fat mass and fat fractions of abdominal organs, at three time points: first before the program, then at the end of the six weeks of formula diet and finally, at the end of the program after 15 weeks. Laboratory data are measured before and after the program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Diabetes Type 2, Weight Loss
Keywords
Formula diet

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
Intervention Type
Other
Intervention Name(s)
Structured weight-loss program
Other Intervention Name(s)
OPTIFAST II Short Program
Intervention Description
During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable. Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling.
Primary Outcome Measure Information:
Title
Change in HbA1c value
Time Frame
measured at week 0 and 15
Secondary Outcome Measure Information:
Title
Change in weight
Time Frame
measured at week 0, 6 and 15
Title
Change in body-mass-index
Time Frame
measured at week 0, 6 and 15
Title
Change in waist circumference
Time Frame
measured at week 0, 6 and 15
Title
Change in hip circumference
Time Frame
measured at week 0, 6 and 15
Title
Change in body composition
Description
Body composition will be assessed with bioimpedance
Time Frame
measured at week 0, 6 and 15
Title
Change in fat fractions of abdominal organs
Description
Fat fraction of abdominal organs will be assessed with magnet resonance imaging
Time Frame
measured at week 0, 6 and 15
Title
Change in visceral fat volume
Description
Visceral fat volume will be assessed with magnet resonance imaging
Time Frame
measured at week 0, 6 and 15
Title
Change in fasting glucose
Time Frame
measured at week 0 and 15
Title
Change in fasting insulin
Time Frame
measured at week 0 and 15
Title
Change in triglycerides
Time Frame
measured at week 0, 6 and 15
Title
Change in cholesterol
Time Frame
measured at week 0, 6 and 15
Title
Change in HDL cholesterol
Time Frame
measured at week 0, 6 and 15
Title
Change in LDL cholesterol
Time Frame
measured at week 0, 6 and 15
Title
Change in alanine transaminase
Time Frame
measured at week 0, 6 and 15
Title
Change in aspartate transaminase
Time Frame
measured at week 0, 6 and 15
Title
Change in gamma-glutamyl transferase
Time Frame
measured at week 0, 6 and 15
Title
Change in alkaline phosphatase
Time Frame
measured at week 0, 6 and 15
Title
Change in uric acid
Time Frame
measured at week 0, 6 and 15
Title
Change in 25-hydroxy-vitamine d3
Time Frame
measured at week 0 and 15
Title
Change in 1,25-dihydroxy-vitamine d3
Time Frame
measured at week 0 and 15
Title
Change in plasma calcium
Time Frame
measured at week 0 and 15
Title
Change in plasma phosphate
Time Frame
measured at week 0 and 15
Title
Change in insulin-like growth factor-1
Time Frame
measured at week 0 and 15
Title
Change in testosterone
Time Frame
measured at week 0 and 15
Title
Change in sex hormone-binding globulin
Time Frame
measured at week 0 and 15
Title
Change in quality of life
Description
Quality of life was determined using SF-12
Time Frame
measured at week 0 and 15
Title
Change in sleep quality
Description
Sleep quality was determined using the Pittsburgh sleep quality index
Time Frame
measured at week 0 and 15
Title
Change in diet history
Description
7-day food record brought in at weeks 0 and 15 will be analyzed for macronutrient intake
Time Frame
measured at week 0 and 15

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: known type 2 diabetes body-mass-index between 27 and 45 kg/m² Exclusion Criteria: treatment with incretin mimetic drugs < 3 month pregnancy immobilization severe heart, liver or renal failure dementia eating disorder alcoholism
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Markus M Lerch, MD
Organizational Affiliation
Department of Medicine A, University Medicine Greifswald
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medicine Greifswald
City
Greifswald
ZIP/Postal Code
17475
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31318902
Citation
Frost F, Storck LJ, Kacprowski T, Gartner S, Ruhlemann M, Bang C, Franke A, Volker U, Aghdassi AA, Steveling A, Mayerle J, Weiss FU, Homuth G, Lerch MM. A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of Collinsella in obese type 2 diabetics: A pilot study. PLoS One. 2019 Jul 18;14(7):e0219489. doi: 10.1371/journal.pone.0219489. eCollection 2019.
Results Reference
derived

Learn more about this trial

Therapy of Obesity and Diabetes Mellitus Type 2

We'll reach out to this number within 24 hrs